NO763776L - - Google Patents
Info
- Publication number
- NO763776L NO763776L NO763776A NO763776A NO763776L NO 763776 L NO763776 L NO 763776L NO 763776 A NO763776 A NO 763776A NO 763776 A NO763776 A NO 763776A NO 763776 L NO763776 L NO 763776L
- Authority
- NO
- Norway
- Prior art keywords
- floatate
- coagulation
- further purification
- aqueous
- factor
- Prior art date
Links
- 108010054218 Factor VIII Proteins 0.000 claims description 32
- 102000001690 Factor VIII Human genes 0.000 claims description 32
- 229960000301 factor viii Drugs 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- 210000002381 plasma Anatomy 0.000 claims description 22
- 230000000603 anti-haemophilic effect Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 17
- 210000002826 placenta Anatomy 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000012266 salt solution Substances 0.000 claims description 13
- 230000015271 coagulation Effects 0.000 claims description 11
- 238000005345 coagulation Methods 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000005188 flotation Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 231100000732 tissue residue Toxicity 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 229920000831 ionic polymer Polymers 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000007792 addition Methods 0.000 description 10
- 229960004222 factor ix Drugs 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 102100022641 Coagulation factor IX Human genes 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 102100027378 Prothrombin Human genes 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 229940039716 prothrombin Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108010076282 Factor IX Proteins 0.000 description 5
- 208000009292 Hemophilia A Diseases 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000005059 placental tissue Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 230000000027 hemostyptic effect Effects 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001026 thromboplastic effect Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 208000019060 congenital factor VII deficiency Diseases 0.000 description 1
- 208000019059 congenital factor X deficiency Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005966 endogenous activation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- -1 heparin Chemical class 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2550011A DE2550011C2 (de) | 1975-11-07 | 1975-11-07 | Verfahren zur Herstellung eines antihämophilen Mittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO763776L true NO763776L (ja) | 1977-05-10 |
Family
ID=5961172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO763776A NO763776L (ja) | 1975-11-07 | 1976-11-05 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4067964A (ja) |
| JP (1) | JPS6029362B2 (ja) |
| AT (1) | AT358737B (ja) |
| AU (1) | AU500621B2 (ja) |
| BE (1) | BE848111A (ja) |
| CA (1) | CA1077393A (ja) |
| CH (1) | CH630805A5 (ja) |
| DE (1) | DE2550011C2 (ja) |
| DK (1) | DK502176A (ja) |
| ES (1) | ES452923A1 (ja) |
| FI (1) | FI763165A (ja) |
| FR (1) | FR2330408A1 (ja) |
| GB (1) | GB1563009A (ja) |
| IL (1) | IL50847A (ja) |
| IT (1) | IT1063617B (ja) |
| LU (1) | LU76145A1 (ja) |
| NL (1) | NL7612139A (ja) |
| NO (1) | NO763776L (ja) |
| SE (1) | SE7612396L (ja) |
| ZA (1) | ZA766647B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0686385B2 (ja) * | 1980-01-28 | 1994-11-02 | バクスタ−、インタ−ナショナル、インコ−ポレイテッド | 活性プロトロンビン複合体組成物およびその製造方法 |
| US4459288A (en) * | 1981-05-11 | 1984-07-10 | Baxter Travenol Laboratories, Inc. | Therapeutic blood clotting factor compositions and their use |
| DE3625090A1 (de) * | 1986-07-24 | 1988-01-28 | Behringwerke Ag | Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung |
| CA1339946C (en) * | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| JP2931319B2 (ja) * | 1989-03-29 | 1999-08-09 | 吉富製薬株式会社 | 血液凝固第▲ｖｉｉｉ▼因子の製造法 |
| JP3180824B2 (ja) * | 1991-08-30 | 2001-06-25 | シスメックス株式会社 | 血液凝固試薬 |
| IL156843A0 (en) * | 2001-02-05 | 2004-02-08 | Novo Nordisk Healthcare Ag | Combined use of factor vii polypeptides and factor viii polypeptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862002A (en) * | 1962-05-08 | 1975-01-21 | Sanfar Lab Inc | Production of physiologically active placental substances |
| BE713764A (ja) * | 1967-05-01 | 1968-09-16 | Baxter Travenol Lab | |
| BE787961A (fr) * | 1971-08-24 | 1973-02-26 | Behringwerke Ag | Procede d'isolement d'une matiere thromboplastique et medicament contenant ladite matiere |
| DE2262520B2 (de) * | 1972-12-20 | 1979-10-11 | Cutter Laboratories Inc., Berkeley, Calif. (V.St.A.) | Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma |
-
1975
- 1975-11-07 DE DE2550011A patent/DE2550011C2/de not_active Expired
-
1976
- 1976-11-02 ES ES452923A patent/ES452923A1/es not_active Expired
- 1976-11-02 NL NL7612139A patent/NL7612139A/xx not_active Application Discontinuation
- 1976-11-04 FI FI763165A patent/FI763165A/fi not_active Application Discontinuation
- 1976-11-04 CH CH1392076A patent/CH630805A5/de not_active IP Right Cessation
- 1976-11-04 IL IL50847A patent/IL50847A/xx unknown
- 1976-11-04 AT AT819476A patent/AT358737B/de not_active IP Right Cessation
- 1976-11-05 DK DK502176A patent/DK502176A/da unknown
- 1976-11-05 LU LU76145A patent/LU76145A1/xx unknown
- 1976-11-05 AU AU19341/76A patent/AU500621B2/en not_active Expired
- 1976-11-05 IT IT29084/76A patent/IT1063617B/it active
- 1976-11-05 SE SE7612396A patent/SE7612396L/xx unknown
- 1976-11-05 ZA ZA766647A patent/ZA766647B/xx unknown
- 1976-11-05 CA CA265,060A patent/CA1077393A/en not_active Expired
- 1976-11-05 NO NO763776A patent/NO763776L/no unknown
- 1976-11-05 US US05/739,278 patent/US4067964A/en not_active Expired - Lifetime
- 1976-11-06 JP JP51132782A patent/JPS6029362B2/ja not_active Expired
- 1976-11-08 FR FR7633603A patent/FR2330408A1/fr active Granted
- 1976-11-08 GB GB46384/76A patent/GB1563009A/en not_active Expired
- 1976-11-08 BE BE172170A patent/BE848111A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| LU76145A1 (ja) | 1977-06-03 |
| AT358737B (de) | 1980-09-25 |
| GB1563009A (en) | 1980-03-19 |
| FI763165A (ja) | 1977-05-08 |
| NL7612139A (nl) | 1977-05-10 |
| JPS6029362B2 (ja) | 1985-07-10 |
| FR2330408A1 (fr) | 1977-06-03 |
| AU1934176A (en) | 1978-05-11 |
| DE2550011C2 (de) | 1982-11-25 |
| FR2330408B1 (ja) | 1980-03-14 |
| BE848111A (fr) | 1977-05-09 |
| ZA766647B (en) | 1977-10-26 |
| AU500621B2 (en) | 1979-05-24 |
| IL50847A0 (en) | 1977-01-31 |
| CH630805A5 (de) | 1982-07-15 |
| US4067964A (en) | 1978-01-10 |
| JPS5257310A (en) | 1977-05-11 |
| DK502176A (da) | 1977-05-08 |
| IL50847A (en) | 1980-01-31 |
| CA1077393A (en) | 1980-05-13 |
| SE7612396L (sv) | 1977-05-08 |
| ES452923A1 (es) | 1977-11-16 |
| DE2550011A1 (de) | 1977-05-12 |
| ATA819476A (de) | 1980-02-15 |
| IT1063617B (it) | 1985-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hovig | Aggregation of rabbit blood platelets produced in vitro by saline “extract” of tendons | |
| Margolis | Initiation of blood coagulation by glass and related surfaces | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| NO148142B (no) | Fremgangsmaate ved fremstilling av et blodkoaguleringsfremmende preparat fra humant blodplasma | |
| Duckert et al. | A modification of the thromboplastin generation test | |
| O'brien | The similarity of the action of phosphatidyl-ethanolamine and platelets in blood coagulation | |
| NO142381B (no) | Fremgangsmaate for fremstilling av den antihemofile faktor | |
| Rapaport et al. | The blood clotting properties of rabbit peritoneal leukocytes in vitro | |
| JPS644621B2 (ja) | ||
| US4870166A (en) | Process for preparing high-purity dematan sulphate, and pharmaceutical compositions which contain it | |
| JPS6160614A (ja) | 第８因子製剤およびその製造方法 | |
| JPH0348888B2 (ja) | ||
| NO763776L (ja) | ||
| CA1293941C (en) | Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product | |
| Munro | Properties of an anticoagulant found in the blood of a hemophiliac | |
| van Iwaarden et al. | A novel procedure for the rapid isolation of surfactant protein A with retention of its alveolar-macrophage-stimulating properties | |
| Casillas et al. | Chromatographic behaviour of clotting factors | |
| EP0052874A1 (en) | Method for synthesizing procoagulant factor VIII activity | |
| Fujimoto | Studies on the antitrypsin of serum | |
| FI87044B (fi) | Foerfarande foer framstaellning av ett medel med vilket man kan behandla hemofili a, som aer resistent mot faktor viii. | |
| Seegers et al. | Activation of purified prothrombin with platelets combined with various crude biochemical preparations | |
| Glazko et al. | The mechanism of the action of saliva in blood coagulation | |
| US3993585A (en) | Elevated human lipids control | |
| Hurt et al. | Human Antihemophilic Factor (AHF) Purification A Comparison of Two Procedures | |
| JPS6396132A (ja) | 抗血液凝固物質及びその製法 |